Market Timing with TurnerTrends Provides Great Stock Picks for the Sophisticated Investor   Timing the Market well requires Stock Picks that work
Home Subscribe! Master Portfolios StockMasterPro ETFMasterPro Partners Members
Top 100 Stocks | Search Stocks | Sector Analyzer | Industry Analyzer
New Hot Stock Picks | How we Rate Stocks | Tutorial
My Stock Watch Lists: Add+
Ticker: 

TurnerTrends Stock Rating Report for BPAX

Data valid for week beginning July 14, 2008

Ticker Company Name
BPAX   [News] BioSante Pharmaceuticals Inc
Company Profile
"BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops hormone therapy products to treat men and women. The company also engages in developing its proprietary calcium phosphate nanotechnology (CaP) primarily for aesthetic medicine, novel vaccines, and drug delivery. Its hormone therapy products include LibiGel, a transdermal testosterone gel, which is in Phase III development for the treatment of female sexual dysfunction- Elestrin, a transdermal estradiol gel for the treatment of menopausal symptoms in women- Bio-T-Gel, a transdermal testosterone gel for the treatment of hypogonadism or testosterone deficiency in men- and The Pill-Plus for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives. The company's CaP products in development comprise BioLook, which is facial line filler in development using proprietary CaP technology in the area of aesthetic medicine- BioVant for the treatment of viral and bacterial infections and autoimmune diseases- BioOral, a delivery system using CaP technology for oral-buccal-intranasal administration of proteins and other therapies- and BioAir, a delivery system using CaP technology for inhalable versions of proteins and other therapies. The company was founded in 1996 and is based in Lincolnshire, Illinois."

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Technical Chart (3 year) Sector Chart Industry Chart

BPAX Technical Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for BPAX. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for BioSante Pharmaceuticals Inc next week. Sign up today and start making money!

FREE TRIAL!!


Stock Information
Friday's Close $4.46
Volume Avg. 94590 shares
Industry Biotechnology
Sector Healthcare
Our Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
Stock Financials
Profit Margin .00%
Operating Margin -2125.09%
Debt-to-Equity .00%
P/E ttm 0.00
EPS ttm $-0.360
EBITDA $-10,670,000
Total Revenue $Unknown
Market Cap $116,370
Annual Dividend $.00
Yield .000%
ROE -44.30%
Revenue Growth Rate Quarterly 23.50%
Earnings Growth Rate Quarterly 0.00%
Earnings Growth Rate Yearly 0.00%
Revenue Growth Rate Average 0.00%
Earnings Growth Rate Average 0.00%
Institutional Ownership Members Only
Value Rating Members Only
TurnerTrends Score Members Only


Latest News

Fri, 18 Jul 2008 21:15:55 Etc/GMTBIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (EDGAR Online)
Wed, 16 Jul 2008 12:00:00 Etc/GMTBioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for Expanded Indication of LibiGel(R) in FSD (Business Wire)
Sat, 28 Jun 2008 01:37:41 Etc/GMTLargest small-cap weekly decline since February (SmallCapInvestor.com)
Mon, 23 Jun 2008 08:35:00 Etc/GMTLet's Talk About Sex: Discussing Intimacy Issues With Your Doctor (Business Wire)
Fri, 20 Jun 2008 13:13:37 Etc/GMTUAL, Royale Energy and China Precision Steel lead small-cap volume in pre-market (SmallCapInvestor.com)
Thu, 19 Jun 2008 12:08:48 Etc/GMTMarcial: BioSante May Be Buyout Bait (at BusinessWeek)
Mon, 16 Jun 2008 12:00:00 Etc/GMTStephen M. Simes, BioSante Pharmaceuticals President and CEO, To Make Two Presentations At The BIO International Convention (Business Wire)
Fri, 13 Jun 2008 21:25:25 Etc/GMTBIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (EDGAR Online)
Fri, 13 Jun 2008 15:37:55 Etc/GMTBioSante Pharmaceuticals, Asta Funding and Perfect World Ltd lead small-cap percentage gainers (SmallCapInvestor.com)
Thu, 12 Jun 2008 12:00:00 Etc/GMTBioSante Pharmaceuticals VP of Clinical Development To Present at The Endocrine Society's 90th Annual Meeting (Business Wire)
Tue, 10 Jun 2008 14:55:10 Etc/GMTBioSante Pharma retains Deutsche Bank as adviser (AP)
Tue, 10 Jun 2008 12:00:00 Etc/GMTBioSante Pharmaceuticals Engages Deutsche Bank As Its Strategic Advisor (Business Wire)
Wed, 4 Jun 2008 00:00:00 Etc/GMTForm 10 K for BioSante Pharmaceuticals, Inc. (WILink)
Tue, 3 Jun 2008 08:35:00 Etc/GMTNew Medical Research Study for Women Who've Lost That Loving Feeling (Business Wire)
Tue, 20 May 2008 13:32:24 Etc/GMTBIOSANTE PHARMACEUTICALS INC Financials (EDGAR Online Financials)
Wed, 14 May 2008 12:00:00 Etc/GMTBioSante Pharmaceuticals to Present at Two International Health Care Conferences (Business Wire)
Fri, 9 May 2008 21:00:41 Etc/GMTBIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (EDGAR Online)
Fri, 9 May 2008 21:00:06 Etc/GMTBIOSANTE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (EDGAR Online)
Fri, 9 May 2008 21:00:00 Etc/GMTBioSante Pharmaceuticals Reports First Quarter 2008 Financial Results (Business Wire)
Thu, 1 May 2008 12:00:00 Etc/GMTBioSante Pharmaceuticals to Present at Deutsche Bank Health Care Conference (Business Wire)
News provided by Yahoo! Finance
Home | Stock Portfolios | Stock Ratings | Top 100 Stocks | New Hot Stock Picks | Sector Analyzer | Industry Analyzer | Member's Area | Articles | FAQ | Contact Us | Terms of Use | Advertise
(C) Copyright TurnerTrends, Inc.  All Rights Reserved.

*Past performance does not guarantee future results. TurnerTrends makes no representations or warrants that just because a stock would have made a profit in the past, using TurnerTrends buy recommendations or sell recommendations, it will make any profits in the future. It is possible that these same stocks will lose money in the future using the TurnerTrends stock recommendations.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither TurnerTrends nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the TurnerTrends site, a user agrees not to redistribute the information found therein.